Flagship Ingrevia Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 29-10-2024
- Paid Up Capital ₹ 0.10 M
as on 29-10-2024
- Company Age 3 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -35.34%
(FY 2023)
- Ebitda -36.10%
(FY 2023)
- Net Worth -142.24%
(FY 2023)
- Total Assets 616.46%
(FY 2023)
About Flagship Ingrevia
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kedar Vidhwans, Shailesh Patel, and Eswaran Iyer serve as directors at the Company.
- CIN/LLPIN
U24290MH2021PTC359714
- Company No.
359714
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Apr 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Flagship Ingrevia?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shailesh Patel  | Director | 29-Apr-2021 | Current |
| Kedar Vidhwans | Director | 29-Apr-2021 | Current |
| Eswaran Iyer | Director | 29-Apr-2021 | Current |
Financial Performance of Flagship Ingrevia.
Flagship Ingrevia Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 35.34% decrease in profit. The company's net worth observed a substantial decline by a decrease of 142.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Flagship Ingrevia?
In 2023, Flagship Ingrevia had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Divine Laboratories Pvt. Ltd.Active 30 years 8 monthsKedar Vidhwans and Shailesh Patel are mutual person
Flagship Biotech International Private LimitedActive 13 years 4 monthsKedar Vidhwans and Shailesh Patel are mutual person
- Flagship Biotech FoundationActive 11 months 2 days
Kedar Vidhwans and Shailesh Patel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Flagship Ingrevia?
Flagship Ingrevia has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Flagship Ingrevia, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Flagship Ingrevia's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
